|Reference||No of patient studied||Complications of vaccine||Main conclusions||Study quality|
|Crespo JF, et al. (2002) ||-17 seronegative patients completed vaccination protocol.||
-No secondary effect of vaccination detected.|
-None of the subsequently seroconverted patients who received kidney transplant presented with VZV disease (up to 18 months post renal transplant).
|-Systematic vaccination prior to transplantation could prevent severe varicella.||Level 2|
|Scanlon-Kohlroser CA,et al. (2002) ||
-A single case of 51yo woman at 6 months post-renal transplant developed a mild rash.|
-She had daily household contact with 15-month old twins vaccinated 40 days ago.
|-Characteristic popular and vesicular rash over the face, trunk, extremities. No dissemination. Confirmed with positive VZV IgG 2 weeks later.||
-Transmission from those vaccinated to susceptible individuals are rare and typically occurs only if these patients develop a rash.|
- Contact cases develop a subclinical infection or mild illness; suggesting vaccine virus remains attenuated when vaccinated.
|Geel AL, et al. (2006) ||-11 seronegative patients have been vaccinated with two doses VZV vaccine.||- No side effects, no fever, or skin lesions among all vaccinated patients.||-Vaccination should be performed in this group of patients in view of potentially lethal complications of primary varicella infection.||Level 2|
|Kho MML, et al. (2016) ||-52 seronegative patients given two doses of VZV vaccine.||
-No severe vaccine-related adverse events were reported.|
- One had pain at injection site.
-Two had zoster (3 months and 9 years post vaccination)
-One patient developed mild varicella (18 days post vaccination).